Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
NCT06982820
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Depressive Disorder, Major
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 22 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GrayMatters Health Ltd.
- Last updated on ClinicalTrials.gov
- May 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Rhode Island · 1
- Butler Hospital · Providence, RI
Texas · 1
- Houston Center For Advanced Psychiatric Treatment · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.